Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq:GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that on May 1, 2023, the Compensation Committee of Galera’s board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 315,000 shares of its common stock to three new employees.
Related news for (GRTX)
- Galera Therapeutics completes acquisition of Nova Pharmaceuticals
- Galera Announces Board Approval of Complete Liquidation and Dissolution
- Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
- Galera Adopts Limited Duration Stockholder Rights Agreement
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
